

LATE-BREAKER ABSTRACT SESSION

Ludivine Demessine

Adherence 2018 · June 8-10 · Miami





Gap between HIV diagnosis and prescribed ART among 11,450 PLWHIV aged >65: a nationwide study in France

Ludivine Demessine¹, L. Peyro-Saint-Paul, F. Chaillot, E. Morilland-Lecoq, JJ Dutheil, JJ Parienti ¹ University of Caen Normandie





I have no conflicts of interest to declare





Describe the cascade of HIV care between diagnostic and ART delivery, among elderly PLWHIV in France





 Magnitude of the gap in France between "HIV diagnosed" and "On antiretroviral therapy" in 2016

• Predictors of not receiving ART

Edward M. Gardner, Clinical infectious diseases, 2011



- Design: Cross-sectional analysis of all reimbursed care data in 2016 from the French retrospective population based cohort study POPVIH65
- Database: national healthcare system (SNIIRAM)
- Inclusion criteria:
 - Patients aged > 65 yo
 - With a chronic long-term illness for HIV (ICD-10 codes B20 to B24 and Z21)

Background Aim of the study Methods Results Limitations Conclusion

Treated patients = patients who received at least one ART in 2016 Untreated patients = patients who received no antiretroviral drug in 2016

Estimation of the rate of untreated patients

Univariate and multivariate analysis to identify predictors of being treated/untreated

Results **Baseline** characteristics **HIV** patients (n= 11,450) Age, years Mean ± SD 71.3 ± 5.1 34% Median [range] 70 [66-98] 7,909 (69%) Male, n (%) Median HIV duration (IQR), years 14.5 (8.7-19.7) 46% Diagnosis in 2016, n(%) 254 (2%) 1 month - 10 years, n(%) 3,163 (28%) 11 - 20 years, n(%) 5,358 (47%) > 20 years, n(%) 2,675 (23%) Co-medications (non-ARV), median (IQR) 13.0 (8-20) Concomitant diseases (non-HIV), median (IQR) 2.0 (1-3) 20% Abrevations: ARV, Antiretroviral; SD, Standard Deviation; IQR, Interguartile Range

9



Background Aim of the study Methods Results Limitations Conclusion Multivariate analysis

	Odds Ratio [CI 95%]	p value
Sex		
Male	Ref	-
Female	4.0 [3.7-4.5]	< 0.001
Age [*] , 10 years	1.2 [1.1-1.3]	< 0.001
HIV duration		
> 20 years	Ref	-
11 - 20 years	2.1 [1.8-2.5]	< 0.001
1 month - 10 years	3.1 [2.6-3.6]	< 0.001
Diagnosis in 2016	9.9 [7.3-13.4]	< 0.001
Alzheimer disease and other dementia	2.5 [1.6-4.0]	< 0.001

Abbrevation: CI, Confidence Interval

Adjusting for geographic region, number of co-medications and number of comorbidities

An OR above 1 indicates a lower likelihood of ART receiving



• No clinical data for CD4 cells and RNA HIV

 Physician prescription may not be followed by drug delivery

Adherence analysis in process

Background	Aim of the study	Methods	Results	Limitations	Conclusion					
Alarming results: 1 out 5 ageing PLWHIV not received										

- Who are these untreated patients ?
- Why ?
- Hypothesis:
 - Poly-pharmacy
 - Risk of toxicity
 - Low perceived benefit
 - Stigmatization



Acknowledgments

Steering committee: L. Peyro-Saint-Paul¹, F. Chaillot¹, E. Morilland-Lecoq¹, JJ Dutheil¹, M. Gabbas², E. M. Gardner³, J. Ghosn^{4,5}, JJ Parienti^{1,6,7}

¹Caen University Hospital, Biostatistics and Clinical Research, CAEN, France

²CNAMTS (Caisse nationale de l'assurance maladie des travailleurs salariés), PARIS, France

³Denver Health Medical Center, DENVER, Colorado, USA

⁴INSERM UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Univeristé Pierre et Marie Curie, PARIS, France[.]

⁵Paris Descartes University, Sorbonne Paris Cité, PARIS, France.

⁶Caen University Hospital, Infectious Diseases, CAEN, France

⁷University of Caen Normandy, EA2656 Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), CAEN, France









Supplementary data

Overview of SNIIRAM extraction

A row = 1 reimbursed healthcare act for 1 patient

Study identifier	Year of birth	Resid. area	Sex	Joints variables used to linked each row to the corresponding healthcare act detailed in other tables (e.g. drugs, physician consultations, hospitalizations,)									
NUM_ENQ	BEN_NAI_ANN	BEN_RES_DPT	BEN_SEX_COD	DCT_ORD_NUM	FLX_TRT_DTD	FLX_DIS_DTD	FLX_EMT_NUM	FLX_EMT_ORD	FLX_EMT_TYP	PRS_NAT_REF	PRS_ORD_NUM	REM_TYP_AFF	ORG_CLE_NUM
POPVIH65_10000012	1941	002	2	2945	2/3/2016	1/4/2016	11	0	1	3385	2	1	01M021506
POPVIH65_10000012	1941	002	2	2946	2/3/2016	1/4/2016	11	0	1	3313	1	1	01M021506
POPVIH65_10000012	1941	002	2	2935	2/3/2016	1/4/2016	11	0	1	3313	1	1	01M021506
POPVIH65_10000012	1941	002	2	2937	2/3/2016	1/4/2016	11	0	1	3313	1	1	01M021506
POPVIH65_10000012	1941	002	2	2947	2/3/2016	1/4/2016	11	0	1	3390	2	1	01M021506
POPVIH65_10000012	1941	002	2	2948	2/3/2016	1/4/2016	11	0	1	3312	1	1	01M021506
POPVIH65_10000012	1941	002	2	2939	2/3/2016	1/4/2016	11	0	1	3313	1	1	01M021506
POPVIH65_10000012	1941	002	2	1795	13/6/2016	1/7/2016	11	0	1	3313	2	1	01M021506
POPVIH65_10000012	1941	002	2	1795	13/6/2016	1/7/2016	11	0	1	3386	3	1	01M021506
POPVIH65_10000012	1941	002	2	1794	13/6/2016	1/7/2016	11	0	1	3312	1	1	01M021506
POPVIH65_10000012	1941	002	2	1795	13/6/2016	1/7/2016	11	0	1	3313	1	1	01M021506
POPVIH65_10000012	1941	002	2	1794	13/6/2016	1/7/2016	11	0	1	3312	2	1	01M021506
POPVIH65_10000012	1941	002	2	1794	13/6/2016	1/7/2016	11	0	1	3385	3	1	01M021506

#ADHERENCE2018

#ADHERENCE2018



Univariate analysis

Basolino charactoristics	HIV patients	HIV patients without	HIV patients with	n value	
Dasenne characteristics	(n= 11,450)	ART (n =2,374)	ART (n=9,076)	p value	
Mean age ± SD, years	71.3 ± 5.1	71.5 ± 5.7	71 .3 ± 4.9	0.07	
Male, n (%)	7,909 (69%)	1,075 (45%)	6 <mark>,</mark> 834 (75%)	< 0.0001	
Median HIV duration (IQR), years	14.5 (8.7-19.7)	10.8 (6.8-14.2)	16.2 (9.5-20.3)	< 0.0001	
Diagnosis in 2016, n(%)	254 (2%)	119 (5%)	135 (1%)		
1 month - 10 years, n(%)	3,163 (28%)	891 (37%)	2,272 (25%)		
11 - 20 years, n(%)	5,358 (47%)	1,112 (47%)	4,246 (47%)		
> 20 years, n(%)	2,675 (23%)	252 (11%)	2,423 (27%)		
Geographic repartition, n (%)				< 0.0001	
Paris area	3,910 (34.1%)	840 (35.4%)	3,070 <mark>(</mark> 33.8%)		
South-East	2,258 (19.7%)	341 (20.3%)	1,777 (19.6%)		
Others regions	5,282 (46.1%)	1,053 (44.4%)	4,229 (46.6%)		
Co-medications (non-ARV), median (IQR)	13.0 (8-20)	9.5 (0-17)	14.0 (9-21)	< 0.0001	
Concomitant diseases (non-HIV), median (IQR)	2.0 (1-3)	1.0 (0-3)	2.0 (1-3)	< 0.0001	
Main concomitant diseases, n (%)					
Cardiovascular disease	6,877 (60%)	1,039 (44%)	5,838 (64%)	< 0.0001	
Dyslipidemia	4,414 (39%)	420 (18%)	3,994 (44%)	< 0.0001	
Anxiety, sleep disorders	2,266 (20%)	331 (14%)	1,935 (21%)	< 0.0001	
Diabetes	2,042 (18%)	314 (13%)	1,728 (19%)	< 0.0001	
Cancer	1,554 (14%)	410 (17%)	1,144 (13%)	< 0.0001	

Abrevations: ART, Antiretroviral Therapy; SD, Standard Deviation; IQR, Interquartile Range